Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: a Dimensional Approach
Part of paid clinical trials in Houston, Texas.
- Sponsor
- The University of Texas Health Science Center, Houston
- Study ID
- NCT03705715
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Neuropsychiatric Syndromes
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Accepted
Interventions
- PET with radiotracer [11C]PBR-28 ( or [11C]ER176) — DRUG\[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
- Affective challenge — OTHERAffective challenge is the induction of, for example, mood or affective pain.
Study Details
The purpose of this research is to determine whether there is more extensive inflammation in the brain of people with clinical evidence of neuropsychiatric syndromes, such as mood disorder, chronic pain syndrome, dementia, traumatic brain injury, or substance abuse. The research will also explore whether there is more inflammation in patients with more neuropsychiatric symptoms. Inflammation in the brain will identified by using Positron Emission Tomography (PET) with the radiotracer \[11C\]PBR-28 or \[11C\]ER176.
Key Dates
- Start date
- May 1, 2017
- Status verified
- Mar 2025
- Primary completion
- Aug 31, 2028
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: PET with radiotracer [11C]PBR-28 or [11C]ER176PET with radiotracer \[11C\]PBR-28 or \[11C\]ER176 will be performed. \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
- Experimental: PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challengePET with radiotracer \[11C\]PBR-28 or \[11C\]ER176 will be performed. \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
Primary Outcome Measure
Level of TSPO expression as quantified by PET imaging to detect binding of the TSPO radiotracer [11C]PBR-28 [ Time Frame: obtained during PET scanning (between 1:30 PM and 3 PM) at study baseline within a few days of study enrollment ]
Central Contacts
- Alan Prossin, MBBS713-486-2836
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| BBSB at UTHealth | Houston | Texas | 77054 |